Scholar Rock Holding Corp
$ 45.20
3.88%
04 Dec - close price
- Market Cap 4,438,344,000 USD
- Current Price $ 45.20
- High / Low $ 45.50 / 42.83
- Stock P/E N/A
- Book Value 2.47
- EPS -3.15
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.77 %
- ROE -2.18 %
- 52 Week High 46.98
- 52 Week Low 22.71
About
Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing targeted therapies leveraging the TGF-beta superfamily of proteins for serious diseases. The company's innovative pipeline addresses critical conditions such as muscular dystrophy and various cancers, showcasing its commitment to transforming patient outcomes through advanced scientific research. With a strong emphasis on strategic collaborations, Scholar Rock aims to expedite the development of its groundbreaking treatment modalities, positioning itself as a key player in the biopharmaceutical landscape.
Analyst Target Price
$47.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-17 | 2025-08-06 | 2025-05-05 | 2025-03-17 | 2024-11-12 | 2024-08-08 | 2024-05-07 | 2024-03-19 | 2023-11-07 | 2023-08-09 | 2023-05-09 | 2023-03-07 |
| Reported EPS | -0.9 | -0.98 | -0.67 | -0.61 | -0.6644 | -0.6 | -0.59 | -0.5 | -0.53 | -0.47 | -0.49 | -0.46 |
| Estimated EPS | -0.8458 | -0.66 | -0.7076 | -0.6288 | -0.6 | -0.61 | -0.51 | -0.49 | -0.52 | -0.56 | -0.58 | -0.57 |
| Surprise | -0.0542 | -0.32 | 0.0376 | 0.0188 | -0.0644 | 0.01 | -0.08 | -0.01 | -0.01 | 0.09 | 0.09 | 0.11 |
| Surprise Percentage | -6.4081% | -48.4848% | 5.3137% | 2.9898% | -10.7333% | 1.6393% | -15.6863% | -2.0408% | -1.9231% | 16.0714% | 15.5172% | 19.2982% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRRK
2025-10-17 20:15:00
Scholar Rock announced the grant of inducement equity awards to 6 newly hired employees, totaling 114,500 shares of common stock, under Nasdaq Listing Rule 5635(c)(4). These awards consist of stock options and restricted stock units, with vesting schedules tied to continued employment. The grants are part of the company's 2022 Inducement Equity Plan, designed to attract new talent.
2025-10-15 21:25:33
Scholar Rock's stock (NASDAQ:SRRK) dropped 6.4% to $32.08 on Tuesday with increased trading volume. Analysts have a consensus "Buy" rating and a target price of $48.60, while Weiss Ratings suggests a "sell." Insider trading shows mixed signals, with one director selling and another buying a significant number of shares.
2025-10-15 15:44:54
Truist Financial analyst Srikripa Devarakonda has reiterated a Buy rating for Scholar Rock (SRRK.US). The analyst has a 46.9% success rate and an average return of 9.1% over the past year, according to TipRanks data. The article also includes general disclaimers about the informational nature of the content and investment risk.
2025-10-14 15:13:24
This article reports that Scholar Rock's stock has fallen due to the FDA issuing an Official Action Indicated (OAI) for a Catalent manufacturing site. The OAI suggests significant issues at the Catalent facility, which could impact products manufactured there.
2025-10-14 10:12:00
Scholar Rock Holding Corp (NASDAQ:SRRK) announced that Novo Nordisk informed them of an "official action indicated" status from the FDA for the Catalent Indiana, LLC facility, owned by Novo Nordisk, following a recent inspection. This classification suggests conditions warranting regulatory action, although specific details were not provided. This development may impact Scholar Rock's biologics license application resubmission for its spinal muscular atrophy drug, apitegromab, which has already faced delays due to procedural issues at a Catalent manufacturing site.
2025-10-14 09:32:46
Scholar Rock Holding (SRRK) is gaining attention due to a new analyst initiation from Bank of America Securities and significant insider buying. While its price-to-book ratio suggests overvaluation compared to the biotech sector, a Discounted Cash Flow model indicates a deep discount to its estimated fair value, highlighting a potential market mispricing. The article discusses these differing valuation perspectives and potential risks for investors.
